Home > Companies > Lucas Medical Inc.

Lucas Medical Inc.

lucasmedicalglobal.com

Lucas Medical, Inc. is a California based medical device manufacturing organization, was established to develop, manufacture and market superior alternatives to existing vascular products. The Company was incorporated in the State of California in September 1994. Innovation, R&D and customer demand for cutting edge products and services drives our success.We do business globally with sales and distribution presence in U.S.A, Germany, Italy, Spain, Sweden, Turkey , Mexico, Chile, Brazil, Israel, Japan, India and Sri Lanka.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

8th International Conference on Bio-Sensing Technology

Conference

Related News

Research

CELYAD ONCOLOGY ANNOUNCES CLOSING OF $32.5 MILLION PRIVATE PLACEMENT WITH FORTRESS INVESTMENT GROUP AFFILIATE

Celyad Oncology SA | December 09, 2021

Celyad Oncology SA, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, announced the closing of its previously announced private placement with an affiliate of Fortress Investment Group. The Company issued 6,500,000 ordinary shares at a price of USD 5.00 for gross proceeds of USD 32.5 million. The Company intends to use net proceeds from the private placement to fund research and developme...

Cell and Gene Therapy, Industry Outlook

SLINGSHOT BIOSCIENCES UNVEILS REVOLUTIONARY FLUORESCENT PROTEIN CONTROL SERIES TO ENHANCE FLOW CYTOMETRY ANALYSIS

Businesswire | July 17, 2023

Slingshot Biosciences, Inc. a leading provider of cell mimic control products, is proud to announce the launch of its new SpectraComp fluorescent protein series collection. This groundbreaking series provides scientists with a cutting-edge fluorescent protein control platform for use in flow cytometry analysis. By genetically modifying T cells and other immune cells in humanized mice to express fluorescent reporter proteins, including eGFP and mCherry, scientists are able to obs...

Cell and Gene Therapy

LUNAPHORE AND NUCLEAI ANNOUNCE A PARTNERSHIP TO PROVIDE AIPOWERED SPATIAL BIOLOGY ANALYSIS TO ACCELERATE DRUG DEVELOPMENT

Lunaphore and Nucleai | September 09, 2022

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data announced a collaboration to accelerate the discovery of novel biomarkers and drug targets using the latest spatial imaging and machine learning technologies. “We are thrilled to announce the partnership with Lunaphore and...

MedTech

LYSANDO AG AND AMICOGEN INC. SIGN GENERAL DEVELOPMENT AGREEMENT

Lysando AG and Amicogen Inc. | October 19, 2022

Lysando AG market leader in the field of antimicrobial proteins has signed a general development agreement with Amicogen Inc., a publicly traded biotechnology company and CDMO headquartered in South Korea. In August last year, Lysando and Amicogen entered into a strategic partnership backed up by a mutual participation model. This collaboration has since been further intensified, now culminating in aforementioned general development agreement. " Read More

Research